Sleep Shapphire’s innovative design and biosensors will allow us to better control the disease.

 

Obstructive Sleep Apnea Syndrome (OSA) is a highly common disorder affecting 2% to 5% of women and 3% to 7% of the middle-aged adult population. 

 

There is evidence that patients with OSAS have a higher risk of developing cardiovascular diseases such as: arterial hypertension, cardiac arrhythmias, ischemic heart disease and stroke. 

 

That is why it is important to develop new therapeutic alternatives to improve the quality of life of these patients.

 

At Giromed together with our group of bio-technologists, doctors, biologists and engineers we are developing an effective, safe and comfortable solution for the treatment of OSAS.